Evgen Pharma Share Chat (EVG)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Evgen Pharma	LSE:EVG	London	Ordinary Share	GB00BSVYN304	ORD 0.25P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	17.00p	16.00p	18.00p	17.00p	17.00p	17.00p	0	08:00:00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.0	-3.6	-4.2	-	12.46

Evgen Pharma Share Discussion Threads

Showing 451 to 473 of 475 messages

Chat Pages: 19 18 17 16 15 14 13 12 11 10 9 8 Older

Date	Subject	Author	Discuss
14/7/2017 17:22	Here is a great article summarising the research into the benefits of Sulforaphane with links to the scientific studies for each claim. A very neat summary, worth a look. hTTps://selfhacked.com/blog/panacea-benefits-broccoli-sprouts-sulforaphane/#My_Experience_With_Broccoli_Sprouts	pdt	Read Full Thread Reply
28/6/2017 15:27	Another article about the Cancer fighting properties of Sulforaphane this time from results of work at a Korean University; hTTps://survivingmesothelioma.com/compound-in-broccoli-may-enhance-mesothelioma-treatment-with-cisplatin/	pdt	Read Full Thread Reply
26/6/2017 10:33	There's a new Evgen presentation/Podcast on Directors talk, it's well worth a listen, quite a few new insights I thought: http://www.directorstalk.net/evgen-pharma-plc-investor-presentation-year-end-mar-31-2017/	timbo003	Read Full Thread Reply
26/6/2017 07:38	Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin talks through the Preliminary Results Presentation for the year ended 31 March 2017. http://bit.ly/2t839nF	ga_dti	Read Full Thread Reply
21/6/2017 16:16	Just had a look at the new Hardman Report and it is a good read. I like the new timeline diagram with potentially trials in MS and Autism starting early in 2018. I suspect the MS will be progressed with a pharma partner which is mentioned as an option. £10m cost, 120 patients and two year study period is mentioned. I doubt they will have too much trouble finding a partner, the market size for MS by 2024 I see estimated at $20 billion in one online report. Autism study is also pencilled in as a potential start in early 2018 with 124 patients. So a good chance of four Phase II studies in progression next year :)	pdt	Read Full Thread Reply
21/6/2017 09:44	The new Hardman Report (out this morning) makes a good read. http://hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/20.06.17-making-clinical-progress.pdf It sounds like they still have cash for the next 12 months which should get them to readouts on the two ongoing clinicals, so let's hope at least one of those still looks promising at that time. Good early progress on some of the other putative indications (including Autism and MS) and there are now 40 candidates from the ongoing Spanish sulforophane analogue screening program, so we could hear some thing on that at any time.	timbo003	Read Full Thread Reply
15/6/2017 14:56	Articles on the net today based on research by Lund Uni of Sweden on Sulforaphane and Type 2 Diabetes. hTTp://www.dailymail.co.uk/health/article-4603750/Is-broccoli-secret-weapon-against-diabetes.html Another blockbuster use for SFX-01 ??	pdt	Read Full Thread Reply
14/6/2017 09:26	>>>>PDT Good spot on the Autism study, although I doubt if it will be totally cost free, for example the CT supplies are likely to come from Evgen, but good news nether the less.	timbo003	Read Full Thread Reply
13/6/2017 15:17	I liked this from today's release; "Autism: a third-party, small (40 patient), randomised placebo controlled trial has shown that sulforaphane (delivered as a frozen botanical extract) significantly improved behavioural measures and there are now five clinical trials (with over 300 patients in aggregate) investigating the use of sulforaphane in autism. None of these is using a viable pharmaceutical product. Evgen Pharma has been approached by a UK consortium led by Dr Michael Absoud (St Thomas' Hospital) that wishes to trial SFX-01 for the treatment of autism in children using a randomised double blind Phase II trial. This is a relatively near-term opportunity to initiate an Investigator Initiated Study using non-dilutive grant funding." I assume the market is concerned about funding. It does seem that they will run out of cash before the two trials are completed. However, the STEM trial will have an interim read out, hopefully before that happened and if positive it will be a lot easier to raise the cash needed. Other market moving news could be the Phase II trial in Autism which sounds like it could start soon (next six months?) Doing a quick search for the market size of medications for ADHD suggested around $15 billion per annum worldwide. I was surprised it was that big, so an effective treatment without side effects I assume could do well? I may add more on the dips if there are any.	pdt	Read Full Thread Reply
13/6/2017 09:45	CEO Dr Stephen Franklin talks about its final results for the year ended 31 March 2017. Stephen reminds us of who Evgen Pharma are and what is in the development pipeline at the moment, talks us through the main result highlights and explains when the current clinical trials report, and what else can we expect in terms of news flow between now and then. http://bit.ly/2siBvEb http://uk.advfn.com/imagesnew/2/gb/nl/createthread.gif	ga_dti	Read Full Thread Reply
02/6/2017 11:56	Timbo - sorry, my mistake. I was reading the Hardman report which just mentions ER positive but the clintrials page you linked to is very clear and it is HER2 negative as well. Yes a very positive report yesterday. Good news on safety, only bad news is the slight reporting delay. I saw a comment on another board that a poster was worried about a placing due to the need for more funds which may be an issue due to the delay. The market size for the drug to support hormone treatment in breast cancer is huge, I think the Hardman report estimated $4 billion. If the interim data analysis they are promising mirrors the compassionate use outcome reported this could fly very quickly. They said first half 2018. A good outcome would make a placing quite easy. My only concern is why is this share on a market cap of £14m??? What am I missing?	pdt	Read Full Thread Reply
01/6/2017 22:13	>>>PDT Agreed, positive news, but it's a pity about the slight delay in the anticipated date for the final readout from the trial On the other point: Do you mean the the trial is using ER positive patients rather than HER2 positive patients? ER = estrogen receptor HER2 = human epidermal growth factor receptor 2 See first three inclusion criteria from the Clintrials.gov outline protocol https://clinicaltrials.gov/ct2/show/NCT02970682?term=evgen&rank=2 Inclusion Criteria: 1) Male or female patients 18 years or older (the patient must be the legal age limit to give informed consent within the jurisdiction the study is taking place in); 2) Patients with histologically confirmed estrogen receptor positive (ER+) breast cancer. ER is considered positive if a percentage score of ≥10% of tumour cells staining positive for ER; 3) Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis or on biopsy of a metastasis. HER2 negative is defined by the ASCO/CAP guidelines; .	timbo003	Read Full Thread Reply
01/6/2017 10:32	Positive news. Being able to extend the useful life of hormone treatment is significant. Stage 4 metastatic breast cancer median survival time is 18 months to 2 years. Keeping the cancer in check for an additional 5 or more months must be very welcome if eventually confirmed. Timbo - I think you will find the trial is using HER positive people	pdt	Read Full Thread Reply
01/6/2017 10:13	Note: In this STEM study, all patients were diagnosed as "HER2 negative breast cancer on primary tumour at diagnosis or on biopsy of a metastasis" https://clinicaltrials.gov/ct2/show/NCT02970682?term=evgen&rank=2	timbo003	Read Full Thread Reply
01/6/2017 10:02	Here's some Kaplan Meier plots which give a better picture of survival rates Maybe my estimate of 50% in the last post was a bit high https://www.nature.com/articles/srep45411 .	timbo003	Read Full Thread Reply
01/6/2017 08:09	Found it Five year survival rates are reported to be 22% That's from historical data and survival times are probably improving all the time, but it puts the STEM update into perspective. Q: So what would be the probability of the first patient on the active treatment showing no progression after 24 weeks? A: 50% ????? ( my guestimate) http://www.healthline.com/health/breast-cancer/metastatic-prognosis#Prognosis3	timbo003	Read Full Thread Reply
01/6/2017 07:58	An interesting update this morning: Metastatic breast cancer study (STEM): Final readout put back a bit due to problems with getting more study centres on board, but one patient now completed with no disease progression, so is now continuing treatment on compassionate grounds (Note to self: need to look up stats for % chance of progression for these patients on standard of care) Subarachnoid Haemorrhage study (SAS); Now over one third of the way complete as far as dosing is concerned, looks like they might have had unequal distribution of severity of the condition between the two groups (active vs control) so they need to adjust the protocol to ensure an equal balance. I don't think we can read anything into that in terms of is the drug working (or not). No significant safety issues though, so that's good	timbo003	Read Full Thread Reply
19/4/2017 02:03	Any idea why this price fallen?	wins73	Read Full Thread Reply
15/2/2017 22:43	Excellent. Wonder what will happen when we get closer to full approvals	peterm10	Read Full Thread Reply
15/2/2017 08:14	This week's (unexpected) performance has to be worth an animated gif! I'm not sure what the catalyst is for this recent rise, a patent grant (even in the US) doesn't normally have an effect of this magnitude on the share price.	timbo003	Read Full Thread Reply
27/1/2017 09:49	Bought my first shares here today. The story looks interesting although highly risky at this stage. Thanks Timbo for a very useful header, it helped researching this one. I like the fact that they have the orphan status and that they are funded for both phase IIs. The MS looks very interesting but they have no funds to progress this. They also seem to have a good strategy with IP/patents/licencing in place. Worth a small punt and see how it goes. From memory I think Northland have a 97p target which is also encouraging!	pdt	Read Full Thread Reply
23/1/2017 14:19	Just spotted this interview (from last week), worth a listen: Evgen Pharma Plc Grossly undervalued say Northland Capital Partners,	timbo003	Read Full Thread Reply
17/1/2017 08:32	Link to the Clintrials.gov summary page for the metastatic breast cancer study (see this morning's announcement): https://clinicaltrials.gov/ct2/show/record/NCT02970682?term=evgen&rank=2	timbo003	Read Full Thread Reply

Chat Pages: 19 18 17 16 15 14 13 12 11 10 9 8 Older